Reclast Kidney Failure Risk Drives FDA To Require New Labeling.
The U.S. Food and Drug Administration (FDA) has approved an update to the drug label for Reclast (zoledronic acid) to better inform healthcare professionals and patients of the risk of kidney (renal) failure. Kidney failure is a rare, but serious, Reclast side effect associated with the use of Reclast in patients with a history of or risk factors for renal impairment. Cases of acute renal failure requiring dialysis or having a fatal outcome following the use of Reclast have been reported to FDA.
Reclast Kidney Failure And Reclast Side Effects
At its onset, kidney failure may be asymptomatic (not producing any symptoms). As kidney function decreases, the symptoms are related to the inability to regulate water and electrolyte balances, to clear waste products from the body, and to promote red blood cell production.
Symptoms include, but may not be limited to the following:
- Shortness of breath
- Generalized swelling
Unrecognized or untreated, life-threatening circumstances can develop.
Reclast is used to treat or to prevent osteoporosis in men or women like you (or a loved one) in various life-stages or who have, or are being treated for, various conditions:
- Women after menopause
- Men and women who take corticosteroids for longer than a year
- Men and women who have Paget’s disease of the bone
Reclast is given as an intravenous infusion in a single dose, sometimes once every 1 to 2 years. The infusion time should be no less than 15 minutes. If you’re taking Reclast, your healthcare professional will likely order a blood test called serum creatinine level before and after each dose of Reclast to determine how well your kidneys are functioning.
If you’ve taken Reclast and experienced kidney failure, or any of the symptoms that indicate kidney failure, contact our Reclast lawyers today. Our Reclast lawyers can help determine if you have a Reclast lawsuit.